Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Show your working: launch revenue is the lagging indicator, and this season proves it

Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.

18 Nov 2026 · CompePharma editorial

Percentages without denominators

Read this week's third-quarter releases in a row and the growth rates blur together. Kura Oncology's KOMZIFTI grew 53% sequentially to $13.9 million. Tonix's TONMYA reached approximately $15 million, up 37% on the second quarter. Autolus reported AUCATZYL revenue of $41.2 million, up 95% year-over-year. Delcath's total revenue rose to $35.1 million from $20.6 million a year earlier. All of these are strong figures, but they use different comparison periods and different starting bases, and none of them says much on its own.

CompePharma's position is that revenue is the lagging indicator of a launch. It tells you what happened last quarter. What it can't tell you is whether the next quarter will look the same. The companies that make the best case this season are the ones that show their working.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

Gross margin is the number that turns a launch into a business

Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.

18 Nov 2026 · CompePharma editorial